292P - Prognostic factors for response and outcome in high body mass index DLBCL patients: a single center retrospective study from South India

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Lymphomas
Aetiology, Epidemiology, Screening and Prevention
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Ranga Raman Ganta
Citation Annals of Oncology (2015) 26 (suppl_9): 85-92. 10.1093/annonc/mdv526
Authors R.R. Ganta, S. Nasaka, L.V. Gandhi, L.S. Maddali, D. Raghunadha Rao
  • Medical Oncology, Nizam's Institute of Medical Sciences, 500082 - Hyderabad/IN



High body mass index (BMI) is an important risk factor influencing the outcome of several types of cancer including lymphomas which is most likely due to altered pharmacodynamics and pharmacokinetics of therapeutic drugs. DLBCL patients are heterogeneous and their outcome depends on the interplay of several prognostic factors. Therefore, it remains unclear which factors have greater impact on response and outcome. We aimed to study various prognostic factors among high BMI DLBCL population.


This is a retrospective single-center analysis of DLBCL patients with high BMI (≥25.0 kg/m2) and was treated with standard chemotherapy +/- Rituximab as first-line therapy between 2002 and 2010. They were analyzed for the factors which influence outcome like age, sex, performance status, B symptoms, stage, bulkiness status, LDH, IPI score, marrow involvement, extranodal involvement. The prognostic factors were compared using multivariate analysis in achievement of complete remission (CR) at the end of treatment and 5 year overall survival (OS).


A total of 88 (19%) among 449 DLBCL patients had high BMI patients, with median age of 46 years (range 14-80) and male preponderance (M:F = 1.26:1). The correlation of achievement of CR with the variables is as follows: age ≤ 60 vs > 60 (p = 0.9), male vs female (p = 0.4), performance status < 2 vs ≥2 (p = 0.02), B symptoms presence vs absence (p = 0.9), early stage vs advanced (p = 0.04), presence vs absence of bulky disease (p = 0.76), normal vs elevated LDH (p = 0.71), low vs intermediate vs high IPI score (p = 0.2), marrow involvement vs absence (p = 0.03), extranodal involvement vs absence (p = 0.41). The correlation of 5 year OS with the variables is as follows: age ≤ 60 vs > 60 (p = 0.7), male vs female (p = 0.9), performance status < 2 vs ≥2 (p = 0.03), B symptoms presence vs absence (p = 0.36), early stage vs advanced (p = 0.01), presence vs absence of bulky disease (p = 0.74), normal vs elevated LDH (p = 1.0), low vs intermediate vs high IPI score (p = 0.4), marrow involvement vs absence (p = 0.01), extranodal involvement vs absence (p = 0.72).


The response and outcome of high BMI DLBCL patients is significantly correlated with the performance status, stage and marrow involvement.

Clinical trial identification



All authors have declared no conflicts of interest.